Enhancing Tumor-specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2010 Jun 15

PMID 20541702

Citations 117

Authors

Seiko Ishida

Frank McCormick

Karen Smith-McCune

Douglas Hanahan

Affiliations

Soon will be listed here.

Abstract

Uptake of the anticancer drug cisplatin is mediated by the copper transporter CTR1 in cultured cells. Here we show in human ovarian tumors that low levels of Ctr1 mRNA are associated with poor clinical response to platinum-based therapy. Using a mouse model of human cervical cancer, we demonstrate that combined treatment with a copper chelator and cisplatin increases cisplatin-DNA adduct levels in cancerous but not in normal tissues, impairs angiogenesis, and improves therapeutic efficacy. The copper chelator also enhances the killing of cultured human cervical and ovarian cancer cells with cisplatin. Our results identify the copper transporter as a therapeutic target, which can be manipulated with copper chelating drugs to selectively enhance the benefits of platinum-containing chemotherapeutic agents.

Citing Articles

Copper-Induced Enhancement of Glioblastoma Tumorigenicity via Cytochrome C Oxidase.

Oliva C, Ali M, Flor S, Griguer C Antioxidants (Basel). 2025; 14(2).

PMID: 40002329 PMC: 11851629. DOI: 10.3390/antiox14020142.

Development and validation of a deep reinforcement learning algorithm for auto-delineation of organs at risk in cervical cancer radiotherapy.

Yucheng L, Lingyun Q, Kainan S, Yongshi J, Wenming Z, Jieni D Sci Rep. 2025; 15(1):6800.

PMID: 40000766 PMC: 11861648. DOI: 10.1038/s41598-025-91362-9.

SLC31A1 promotes chemoresistance through inducing CPT1A-mediated fatty acid oxidation in ER-positive breast cancer.

Li X, Ge J, Wan M, Feng T, Li X, Zhang H Neoplasia. 2025; 61:101125.

PMID: 39904115 PMC: 11847129. DOI: 10.1016/j.neo.2025.101125.

Targeting ion channels: innovative approaches to combat cancer drug resistance.

Shi Q, Yang Z, Yang H, Xu L, Xia J, Gu J Theranostics. 2025; 15(2):521-545.

PMID: 39744692 PMC: 11671388. DOI: 10.7150/thno.103384.

Involvement of copper in cell death and cancer.

Xie J, Su Y, Shang W, Wu Y, He J, Li T Apoptosis. 2024; 30(1-2):488-505.

PMID: 39702813 DOI: 10.1007/s10495-024-02059-9.

References

Holzer A, Manorek G, Howell S . Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006; 70(4):1390-4. DOI: 10.1124/mol.106.022624. View

Lustberg M, Edelman M . Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol. 2007; 8(1):38-46. DOI: 10.1007/s11864-007-0020-6. View

Gallagher D, Milowsky M, Bajorin D . Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer. 2008; 113(6):1284-93. DOI: 10.1002/cncr.23692. View

Bull P, Thomas G, Rommens J, FORBES J, Cox D . The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993; 5(4):327-37. DOI: 10.1038/ng1293-327. View

Hainsworth J, Grosh W, BURNETT L, Jones 3rd H, Wolff S, Greco F . Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med. 1988; 108(2):165-70. DOI: 10.7326/0003-4819-108-2-165. View

Nose Y, Kim B, Thiele D . Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. Cell Metab. 2006; 4(3):235-44. DOI: 10.1016/j.cmet.2006.08.009. View

Jamieson E, Lippard S . Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev. 2001; 99(9):2467-98. DOI: 10.1021/cr980421n. View

Elson D, Riley R, Lacey A, Thordarson G, Talamantes F, Arbeit J . Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 2000; 60(5):1267-75. View

Coussens L, Hanahan D, Arbeit J . Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol. 1996; 149(6):1899-917. PMC: 1865365. View

10.

Louie K, Ozols R, Myers C, Ostchega Y, Jenkins J, Howser D . Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol. 1986; 4(11):1579-85. DOI: 10.1200/JCO.1986.4.11.1579. View

11.

Hall M, Okabe M, Shen D, Liang X, Gottesman M . The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2007; 48:495-535. DOI: 10.1146/annurev.pharmtox.48.080907.180426. View

12.

Lowndes S, Adams A, Timms A, Fisher N, Smythe J, Watt S . Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res. 2008; 14(22):7526-34. DOI: 10.1158/1078-0432.CCR-08-0315. View

13.

Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

14.

Hussain S, Ma Y, Cullen M . Management of metastatic germ cell tumors. Expert Rev Anticancer Ther. 2008; 8(5):771-84. DOI: 10.1586/14737140.8.5.771. View

15.

Brewer G, Merajver S . Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review. Integr Cancer Ther. 2003; 1(4):327-37. DOI: 10.1177/1534735402238185. View

16.

Carrick S, Ghersi D, Wilcken N, Simes J . Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2004; (2):CD003374. DOI: 10.1002/14651858.CD003374.pub2. View

17.

Tanzi R, Petrukhin K, Chernov I, Pellequer J, Wasco W, Ross B . The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993; 5(4):344-50. DOI: 10.1038/ng1293-344. View

18.

Tao X, Hu W, Ramirez P, Kavanagh J . Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol. 2008; 110(3 Suppl 2):S67-71. DOI: 10.1016/j.ygyno.2008.04.024. View

19.

Brewer G . The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opin Investig Drugs. 2008; 18(1):89-97. DOI: 10.1517/13543780802621859. View

20.

Saif M, Kim R . Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother. 2007; 8(16):2719-27. DOI: 10.1517/14656566.8.16.2719. View